Skip to content
A11334Assembly2025-2026 Session

Let Pharmacists Manage More Meds

Official title

“Expands collaborative drug therapy management by pharmacists”

Sponsor John T. McDonald IIIAD-108+1 co-sponsorAffects Education
Status
In Assembly Committee
Higher Education
Impact
7/10
Significant
Passage
32%

Bill progress

Step 2 of 7

In committee · Higher Education

What's happening

This bill expands collaborative drug therapy management to include physician practices and certain mental health facilities, and streamlines patient consent procedures.

Why it matters

  1. Expands access to collaborative drug therapy management. by allowing these arrangements not only in hospitals and nursing homes, but also in physician practices and certain mental health and substance use disorder facilities—potentially reaching more patients across both urban and rural New York.

  2. Streamlines the consent process. so that patient approval for collaborative drug therapy management can be obtained using the same general consent procedures already in place for health care services, making it less burdensome for both patients and providers and likely increasing participation.

  3. Makes the expanded authority permanent. by removing the sunset (expiration) date on key provisions, providing long-term certainty for pharmacists, physicians, and healthcare facilities that wish to implement these collaborative practices, which could improve medication management and patient outcomes statewide.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Pharmacists

    This bill directly impacts pharmacists by expanding their ability to participate in collaborative drug therapy management in additional healthcare settings, such as physician practices and certain mental health facilities.

  • Physicians and Physician Practices

    Physicians and their practices are newly included as eligible facilities for collaborative drug therapy management, affecting their workflows, patient care models, and collaborative opportunities with pharmacists.

  • Patients

    Patients stand to benefit from expanded access to collaborative drug therapy management, especially in mental health and physician practice settings, and will experience changes in the consent process for participation.

  • Mental Health and Substance Use Treatment Facilities

    Facilities licensed under articles 31 and 32 of the mental hygiene law (mental health and substance use disorder treatment centers) are now included, giving them new opportunities for pharmacist-physician collaboration in medication management.

Headline styles

Let Pharmacists Manage More Meds

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
John T. McDonald III

Assembly Member · Assembly District 108

Chair, Governmental OperationsRules

1 Co-sponsor

History

  1. Referred to higher education

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

11334

IN ASSEMBLY

May 11, 2026

Introduced by COMMITTEE ON RULES -- (at request of M. of A. McDonald) -read once and referred to the Committee on Higher Education

AN ACT to amend the education law, in relation to expanding collaborative drug therapy management; and to amend chapter 21 of the laws of

2011 amending the education law relating to authorizing pharmacists to perform collaborative drug therapy management with physicians in certain settings, in relation to the effectiveness thereof

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph d of subdivision 1 and subdivision 4 of section 6801-a of the education law, as amended by chapter 238 of the laws of 2015, are amended to read as follows:

d. "Facility" shall mean: (i) a teaching hospital or general hospital, including any diagnostic center, treatment center, or hospital-based outpatient department as defined in section twenty-eight hundred one of the public health law; [or] (ii) a nursing home [with an on-site pharmacy staffed by a licensed pharmacist]; (iii) a physician practice; or (iv) a facility licensed, certified, or otherwise authorized pursuant to article thirty-one or article thirty-two of the mental hygiene law, provided, however, for the purposes of this section the term "facility" shall not include dental clinics, dental dispensaries, residential health care facilities and rehabilitation centers.

For the purposes of this section, a "teaching hospital" shall mean a hospital licensed pursuant to article twenty-eight of the public health law that is eligible to receive direct or indirect graduate medical education payments pursuant to article twenty-eight of the public health law.

4. The existence of a written agreement or protocol on collaborative drug therapy management and the patient's right to choose to not participate in collaborative drug therapy management shall be disclosed to any patient who is eligible to receive collaborative drug therapy management. Collaborative drug therapy management shall not be utilized unless the patient or the patient's authorized representative consents, in writing, to such management. If the patient or the patient's authorized

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD15789-01-6

representative consents, it shall be noted on the patient's medical record. If the patient or the patient's authorized representative who consented to collaborative drug therapy management chooses to no longer participate in such management, at any time, it shall be noted on the patient's medical record. Patient consent to participate in collaborative drug therapy management may be obtained through the same process a facility currently utilizes to receive general written consent from patients to receive health care services. In addition, the existence of the written agreement or protocol and the patient's consent to such management shall be disclosed to the patient's primary physician and any other treating physician or healthcare provider.

§ 2. Section 5 of chapter 21 of the laws of 2011, amending the education law relating to authorizing pharmacists to perform collaborative drug therapy management with physicians in certain settings, as amended by section 2 of part P of chapter 57 of the laws of 2024, is amended to read as follows:

§ 5. This act shall take effect on the one hundred twentieth day after it shall have become a law[, provided, however, that the provisions of sections two, three, and four of this act shall expire and be deemed repealed July 1, 2026]; provided, however, that the amendments to subdivision 1 of section 6801 of the education law made by section one of this act shall be subject to the expiration and reversion of such subdivision pursuant to section 8 of chapter 563 of the laws of 2008, when upon such date the provisions of section one-a of this act shall take effect; provided, further, that effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized and directed to be made and completed on or before such effective date.

§ 3. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.